ASCO 2014: Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma
Abstract No: 8594 Background: Carfilzomib (CFZ) is a selective proteasome inhibitor approved in the US…
read more